Loading organizations...
Loading organizations...
Prenetics is a technology company.
Prenetics is a health sciences company that specializes in providing genomic and diagnostic testing services. The company develops and deploys accessible testing solutions encompassing pharmacogenomics, nutrigenomics, cancer screening, and general consumer health insights. Through its advanced testing platforms, Prenetics focuses on delivering personalized information that aims to redefine and support individual health and longevity.
The company was co-founded in 2014 by Danny Yeung and Lawrence Tzang. Danny Yeung has served as the Chief Executive Officer since its inception, bringing a background as a serial entrepreneur to the venture. The foundational insight behind Prenetics was the opportunity to disrupt and decentralize traditional healthcare by making sophisticated genomic and diagnostic information directly available to consumers.
Prenetics serves individuals globally, with a presence across Hong Kong, the United States, and other international markets, empowering them with actionable health intelligence. The company's long-term vision is to advance and democratize consumer health worldwide, enabling people to take a more proactive and informed approach to their well-being and life quality through scientific insights.
Prenetics has raised $100.7M across 4 funding rounds.
Prenetics has raised $100.7M in total across 4 funding rounds.
Prenetics is a genomics-driven health sciences company specializing in consumer genetic testing, early disease screening, and rapid diagnostics, with products like CircleDNA (world's most comprehensive consumer DNA test using whole exome sequencing for 500+ health reports) and Circle HealthPod (CE-IVD point-of-care device delivering PCR-quality results in 20 minutes for COVID-19, influenza, and STDs).[1][3] It serves consumers seeking prevention-focused healthcare, addressing problems like early colorectal cancer detection, infectious disease monitoring, and personalized nutrition via nutrigenomics, while disrupting a $1.3 trillion global healthcare market through decentralized testing.[1][3] Growth momentum includes over 5 million tests performed globally, expanded manufacturing, R&D collaborations with the University of Oxford, and a "dual-engine" strategy targeting $1 billion annual revenue and $1 billion in Bitcoin holdings by 2049.[1][2]
Founded as a leader in genomic and diagnostic testing, Prenetics went public via a merger with Artisan Acquisition Corp on Nasdaq in 2021, marking its pivot to scale globally.[1] The company emerged from expertise in commercializing frontier science, with early traction in COVID-19 testing and consumer DNA kits, evolving into a multi-product ecosystem.[1] Key leadership includes physician-scientist Dr. Senthil Sundaram (Chief Clinical Officer, expert in genetic mutations via next-generation sequencing), Dr. James DiNicolantonio (Chief Nutrition Officer, focused on nutraceuticals), and advisors like Dr. Green (NASA health innovations), Dr. Devkota (microbiome therapies), and Prof. Anton (healthy aging).[4] Backed by in-house R&D from scientists at Exact Sciences and EverlyWell, Prenetics built on University of Oxford technology for breakthroughs like the HealthPod.[1]
Prenetics rides the precision medicine and decentralized diagnostics trend, capitalizing on post-COVID demand for at-home, rapid testing amid rising chronic disease burdens like cancer and metabolic disorders.[1] Timing aligns with genomic advancements (e.g., whole exome sequencing) and AI-driven personalization, positioning it against players like Exact Sciences in a market favoring prevention over treatment.[1][4] Favorable forces include global lab expansion needs and regulatory nods like CE-IVD; it influences the ecosystem by pioneering "Health + Wealth" models, proving multi-engine strategies amplify resilience in volatile markets.[2]
Prenetics is poised to scale its dual-engine revolution, with R&D expansions into microbiome therapies, nutraceuticals, and new assays driving toward $1B revenue goals amid booming telehealth and crypto-health intersections.[1][2][4] Trends like healthy aging tech and point-of-care decentralization will shape its path, potentially evolving it into a transformative leader blending biotech with financial innovation. As a Nasdaq-listed pioneer in genomic disruption, Prenetics exemplifies how prevention-focused tech can redefine healthcare value creation.[1][2]
Prenetics has raised $100.7M in total across 4 funding rounds.
Prenetics's investors include Adrian Cheng, Aryna Sabalenka, Jihan Wu, America, Exodus, GPTX, Kraken, Cindy Chow, Beyond Ventures, eGarden Ventures, mFund, Yuantai Investment Partners.
Prenetics has raised $100.7M across 4 funding rounds. Most recently, it raised $48.0M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 27, 2025 | $48.0M Other Equity | Adrian Cheng, Aryna Sabalenka, Jihan Wu, America, Exodus, GPTX, Kraken | |
| Oct 17, 2017 | $40.0M Series B | Cindy Chow, Beyond Ventures | eGarden Ventures, mFund, Yuantai Investment Partners |
| Mar 16, 2016 | $10.0M Series A | Ping An Ventures | 500 Startups, Capital Union Investments, Coent Venture Partners, Stefan Jung |
| Dec 3, 2014 | $2.6M Seed | Danny Yeung | Joel Neoh, 500 Startups, Coent Venture Partners |